Selected Publications from OnkPat

Denna sida på svenska

OnkPat publications with Impact factor 8 and higher:

2017

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.
Leroy B, Ballinger M, Baran-Marszak F, Bond G, Braithwaite A, Concin N, et al
Cancer Res. 2017 Mar;77(6):1250-1260

Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
Ylitalo E, Thysell E, Jernberg E, Lundholm M, Crnalic S, Egevad L, et al
Eur. Urol. 2017 May;71(5):776-787

Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia.
Ojamies P, Kontro M, Edgren H, Ellonen P, Lagström S, Almusa H, et al
Leukemia 2017 May;31(5):1048-1058

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.
Sartor O, Coleman R, Nilsson S, Heinrich D, Helle S, O'Sullivan J, et al
Ann. Oncol. 2017 May;28(5):1090-1097

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia.
Eldfors S, Kuusanmäki H, Kontro M, Majumder M, Parsons A, Edgren H, et al
Leukemia 2017 Jan;31(1):51-57

TP53 and 53BP1 Reunited.
Soussi T, Kroemer G
Trends Cell Biol. 2017 May;27(5):311-313

Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.
Helgadottir H, Kis L, Ljungman P, Larkin J, Kefford R, Ascierto P, et al
Ann. Oncol. 2017 Apr;():

Inhibiting the system xC(-)/glutathione axis selectively targets cancers with mutant-p53 accumulation.
Liu D, Duong C, Haupt S, Montgomery K, House C, Azar W, et al
Nat Commun 2017 Mar;8():14844

Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes.
Li J, Ivansson E, Klevebring D, Tobin N, Lindström L, Holm J, et al
Clin. Cancer Res. 2017 May;23(10):2584-2592

Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy.
Apellániz-Ruiz M, Tejero H, Inglada-Pérez L, Sánchez-Barroso L, Gutiérrez-Gutiérrez G, Calvo I, et al
Clin. Cancer Res. 2017 Mar;23(5):1227-1235

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.
Ilander M, Olsson-Strömberg U, Schlums H, Guilhot J, Brück O, Lähteenmäki H, et al
Leukemia 2017 May;31(5):1108-1116

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML.
Malani D, Murumägi A, Yadav B, Kontro M, Eldfors S, Kumar A, et al
Leukemia 2017 May;31(5):1187-1195

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Long G, Flaherty K, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al
Ann. Oncol. 2017 May;():

Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients.
He W, Smedby K, Fang F, Olsson H, Margolin S, Hall P, et al
J. Natl. Cancer Inst. 2017 Oct;109(10):

Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy.
Sooriakumaran P, Nyberg T, Akre O, Widmark A, Hamdy F, Graefen M, et al
Eur. Urol. 2017 Apr;():

A zebrafish model discovers a novel mechanism of stromal fibroblast-mediated cancer metastasis.
Liu C, Zhang Y, Lim S, Hosaka K, Yang Y, Pavlova T, et al
Clin. Cancer Res. 2017 Apr;():

Research needs in breast cancer.
Cardoso F, Harbeck N, Barrios C, Bergh J, Cortés J, El Saghir N, et al
Ann. Oncol. 2017 Feb;28(2):208-217

Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force.
Stauder R, Eichhorst B, Hamaker M, Kaplanov K, Morrison V, Österborg A, et al
Ann. Oncol. 2017 Feb;28(2):218-227

Reducing VEGF-B Signaling Ameliorates Renal Lipotoxicity and Protects against Diabetic Kidney Disease.
Falkevall A, Mehlem A, Palombo I, Heller Sahlgren B, Ebarasi L, He L, et al
Cell Metab. 2017 Mar;25(3):713-726

Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.
Taylor C, Correa C, Duane F, Aznar M, Anderson S, Bergh J, et al
J. Clin. Oncol. 2017 May;35(15):1641-1649

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.
Sartor O, Coleman R, Nilsson S, Heinrich D, Helle S, O'Sullivan J, et al
Ann. Oncol. 2017 Feb;():

Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1.
Nagaraj A, Lahtela J, Hemmes A, Pellinen T, Blom S, Devlin J, et al
Cell Rep 2017 Jan;18(3):673-684

Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer.
Saeed K, Rahkama V, Eldfors S, Bychkov D, Mpindi J, Yadav B, et al
Eur. Urol. 2017 Mar;71(3):319-327

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.
Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E, et al
Leukemia 2017 Apr;():

HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.
Kontro M, Kumar A, Majumder M, Eldfors S, Parsons A, Pemovska T, et al
Leukemia 2017 Feb;31(2):301-309

Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma.
Fischer S, Tandstad T, Wheater M, Porfiri E, Fléchon A, Aparicio J, et al
J. Clin. Oncol. 2017 Jan;35(2):194-200

Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers.
Hydbring P, Wang Y, Fassl A, Li X, Matia V, Otto T, et al
Cancer Cell 2017 Apr;31(4):576-590.e8

Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial.
Erlandsson J, Holm T, Pettersson D, Berglund , Cedermark B, Radu C, et al
Lancet Oncol. 2017 Mar;18(3):336-346

Proteogenomics produces comprehensive and highly accurate protein-coding gene annotation in a complete genome assembly of Malassezia sympodialis.
Zhu Y, Engström P, Tellgren-Roth C, Baudo C, Kennell J, Sun S, et al
Nucleic Acids Res. 2017 Mar;45(5):2629-2643

Estrogen Receptor β as a Therapeutic Target in Breast Cancer Stem Cells.
Ma R, Karthik G, Lövrot J, Haglund F, Rosin G, Katchy A, et al
J. Natl. Cancer Inst. 2017 Mar;109(3):1-14

Therapeutic implications of tumor interstitial acidification.
Kolosenko I, Avnet S, Baldini N, Viklund J, De Milito A
Semin. Cancer Biol. 2017 Apr;43():119-133

A multi-step peptidolytic cascade for amino acid recovery in chloroplasts.
Teixeira P, Kmiec B, Branca R, Murcha M, Byzia A, Ivanova A, et al
Nat. Chem. Biol. 2017 Jan;13(1):15-17

Global Curriculum Edition 2016: European Society for Medical Oncology/American Society of Clinical Oncology Recommendations for Training in Medical Oncology.
Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, et al
J. Clin. Oncol. 2017 Jan;35(2):254-255

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
Neoptolemos J, Palmer D, Ghaneh P, Psarelli E, Valle J, Halloran C, et al
Lancet 2017 Mar;389(10073):1011-1024

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
Herold N, Rudd S, Ljungblad L, Sanjiv K, Myrberg I, Paulin C, et al
Nat. Med. 2017 Feb;23(2):256-263

2016

Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Foukakis T, von Minckwitz G, Bengtsson N, Brandberg Y, Wallberg B, Fornander T, et al
JAMA 2016 11;316(18):1888-1896

Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.
Helgadottir H, Höiom V, Tuominen R, Nielsen K, Jönsson G, Olsson H, et al
J. Natl. Cancer Inst. 2016 Nov;108(11):

Pericyte-fibroblast transition promotes tumor growth and metastasis.
Hosaka K, Yang Y, Seki T, Fischer C, Dubey O, Fredlund E, et al
Proc. Natl. Acad. Sci. U.S.A. 2016 Sep;113(38):E5618-27

IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.
Mao Y, van Hoef V, Zhang X, Wennerberg E, Lorent J, Witt K, et al
Blood 2016 Sep;128(11):1475-89

Glioma-induced inhibition of caspase-3 in microglia promotes a tumor-supportive phenotype.
Shen X, Burguillos M, Osman A, Frijhoff J, Carrillo-Jiménez A, Kanatani S, et al
Nat. Immunol. 2016 Nov;17(11):1282-1290

An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors.
Tobin N, Wennmalm K, Lindström L, Foukakis T, He L, Genové G, et al
Clin. Cancer Res. 2016 May;22(10):2417-26

iGEMS: an integrated model for identification of alternative exon usage events.
Sood S, Szkop K, Nakhuda A, Gallagher I, Murie C, Brogan R, et al
Nucleic Acids Res. 2016 Jun;44(11):e109

nanoCAGE reveals 5' UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs.
Gandin V, Masvidal L, Hulea L, Gravel S, Cargnello M, McLaughlan S, et al
Genome Res. 2016 05;26(5):636-48

Guidance Molecule SEMA3A Restricts Tumor Growth by Differentially Regulating the Proliferation of Tumor-Associated Macrophages.
Wallerius M, Wallmann T, Bartish M, Östling J, Mezheyeuski A, Tobin N, et al
Cancer Res. 2016 Jun;76(11):3166-78

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Lipton J, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, et al
Lancet Oncol. 2016 May;17(5):612-21

mTORC1 and CK2 coordinate ternary and eIF4F complex assembly.
Gandin V, Masvidal L, Cargnello M, Gyenis L, McLaughlan S, Cai Y, et al
Nat Commun 2016 Apr;7():11127

Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma.
Mao Y, Eissler N, Blanc K, Johnsen J, Kogner P, Kiessling R
Clin. Cancer Res. 2016 Aug;22(15):3849-59

Gene regulatory mechanisms underpinning prostate cancer susceptibility.
Whitington T, Gao P, Song W, Ross-Adams H, Lamb A, Yang Y, et al
Nat. Genet. 2016 Apr;48(4):387-97

Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.
Dunning A, Michailidou K, Kuchenbaecker K, Thompson D, French J, Beesley J, et al
Nat. Genet. 2016 Apr;48(4):374-86

Estrogen Receptor α Promotes Breast Cancer by Reprogramming Choline Metabolism.
Jia M, Andreassen T, Jensen L, Bathen T, Sinha I, Gao H, et al
Cancer Res. 2016 Oct;76(19):5634-5646

Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?
Papakonstantinou A, Foukakis T, Rodriguez-Wallberg K, Bergh J
J. Clin. Oncol. 2016 May;34(14):1573-9

A multi-step peptidolytic cascade for amino acid recovery in chloroplasts.
Teixeira P, Kmiec B, Branca R, Murcha M, Byzia A, Ivanova A, et al
Nat. Chem. Biol. 2017 Jan;13(1):15-17

Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis.
Georgoudaki A, Prokopec K, Boura V, Hellqvist E, Sohn S, Östling J, et al
Cell Rep 2016 May;15(9):2000-11

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Klionsky D, Abdelmohsen K, Abe A, Abedin M, Abeliovich H, Acevedo Arozena A, et al
Autophagy 2016 ;12(1):1-222

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016.
Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, et al
Ann. Oncol. 2016 Aug;27(8):1378-81

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
O'Brien S, Jones J, Coutre S, Mato A, Hillmen P, Tam C, et al
Lancet Oncol. 2016 Oct;17(10):1409-1418

Spatio-temporal activation of caspase-8 in myeloid cells upon ischemic stroke.
Rodhe J, Burguillos M, de Pablos R, Kavanagh E, Persson A, Englund E, et al
Acta Neuropathol Commun 2016 Aug;4(1):92

Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.
Thielen N, Richter J, Baldauf M, Barbany G, Fioretos T, Giles F, et al
Clin. Cancer Res. 2016 Aug;22(16):4030-8

A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.
Epstein J, Zelefsky M, Sjoberg D, Nelson J, Egevad L, Magi-Galluzzi C, et al
Eur. Urol. 2016 Mar;69(3):428-35

Can ovarian suppression with gonadotropin-releasing hormone analogs (GnRHa) preserve fertility in cancer patients?
Rodriguez-Wallberg K, Turan V, Munster P, Oktay K
Ann. Oncol. 2016 Feb;27(2):357

TAP-ing into TIEPPs for cancer immunotherapy.
Kiessling R
J. Clin. Invest. 2016 Feb;126(2):480-2

ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer.
Manna S, Bostner J, Sun Y, Miller L, Alayev A, Schwartz N, et al
Clin. Cancer Res. 2016 Mar;22(6):1421-31

The Proteome of Primary Prostate Cancer.
Iglesias-Gato D, Wikström P, Tyanova S, Lavallee C, Thysell E, Carlsson J, et al
Eur. Urol. 2016 May;69(5):942-52

A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
Klevebro F, Alexandersson von Döbeln G, Wang N, Johnsen G, Jacobsen A, Friesland S, et al
Ann. Oncol. 2016 Apr;27(4):660-7

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
Ou S, Ahn J, De Petris L, Govindan R, Yang J, Hughes B, et al
J. Clin. Oncol. 2016 Mar;34(7):661-8

Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force.
Stauder R, Eichhorst B, Hamaker M, Kaplanov K, Morrison V, Österborg A, et al
Ann. Oncol. 2017 Feb;28(2):218-227

Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer.
Couch F, Kuchenbaecker K, Michailidou K, Mendoza-Fandino G, Nord S, Lilyquist J, et al
Nat Commun 2016 Apr;7():11375

Down-regulation of the cyclin-dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis.
Guo H, Jing L, Cheng Y, Atsaves V, Lv Y, Wu T, et al
Hepatology 2016 Mar;63(3):898-913

Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort.
Loeb S, Folkvaljon Y, Robinson D, Lissbrant I, Egevad L, Stattin P
Eur. Urol. 2016 Jun;69(6):1135-41

Validation and development of MTH1 inhibitors for treatment of cancer.
Warpman Berglund U, Sanjiv K, Gad H, Kalderén C, Koolmeister T, Pham T, et al
Ann. Oncol. 2016 Dec;27(12):2275-2283

Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia.
Gunnarsson N, Höglund M, Stenke L, Wållberg-Jonsson S, Sandin F, Björkholm M, et al
Leukemia 2016 Jul;30(7):1562-7

Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study.
Dahlén T, Edgren G, Lambe M, Höglund M, Björkholm M, Sandin F, et al
Ann. Intern. Med. 2016 Aug;165(3):161-6

Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors.
Shukla N, Somwar R, Smith R, Ambati S, Munoz S, Merchant M, et al
Cancer Res. 2016 Aug;76(15):4525-34

End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study.
Ahmadi Z, Wysham N, Lundström S, Janson C, Currow D, Ekström M
Thorax 2016 Jun;71(6):510-6

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.
Ilander M, Olsson-Strömberg U, Schlums H, Guilhot J, Brück O, Lähteenmäki H, et al
Leukemia 2017 May;31(5):1108-1116

A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial.
Hagman H, Frödin J, Berglund , Sundberg J, Vestermark L, Albertsson M, et al
Ann. Oncol. 2016 Jan;27(1):140-7

Caspase-3-dependent cleavage of Bcl-xL in the stroma exosomes is required for their uptake by hematological malignant cells.
Vardaki I, Sanchez C, Fonseca P, Olsson M, Chioureas D, Rassidakis G, et al
Blood 2016 Dec;128(23):2655-2665

Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities.
Gréen H, Hasmats J, Kupershmidt I, Edsgärd D, de Petris L, Lewensohn R, et al
Clin. Cancer Res. 2016 Jan;22(2):366-73

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva R, Grosicki S, et al
Lancet Oncol. 2016 Feb;17(2):200-11

Utility of Reporting the Percentage of High-grade Prostate Cancer.
Egevad L, Delahunt B, Samaratunga H, Srigley J
Eur. Urol. 2016 Apr;69(4):599-600

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
Hadji P, Coleman R, Wilson C, Powles T, Clézardin P, Aapro M, et al
Ann. Oncol. 2016 Mar;27(3):379-90

CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil.
Almqvist H, Axelsson H, Jafari R, Dan C, Mateus A, Haraldsson M, et al
Nat Commun 2016 Mar;7():11040

A 21-Gene Expression Assay in Breast Cancer.
Foukakis T, Falato C, Bergh J
N. Engl. J. Med. 2016 Apr;374(14):1386-7

Sisyphean Efforts: Establishing the Correct Risk-Benefit Balance for Adjuvant Therapies.
Bergh J, Pritchard K, Cameron D
J. Clin. Oncol. 2016 Mar;34(9):895-7

Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group.
Feldman D, Lorch A, Kramar A, Albany C, Einhorn L, Giannatempo P, et al
J. Clin. Oncol. 2016 Feb;34(4):345-51

Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.
Nilsson S, Cislo P, Sartor O, Vogelzang N, Coleman R, O'Sullivan J, et al
Ann. Oncol. 2016 May;27(5):868-74

Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients.
Brand J, Hedayati E, Humphreys K, Ludvigsson J, Johansson A, Bergh J, et al
Clin. Cancer Res. 2016 Nov;22(21):5249-5255

Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients.
Hjorth-Hansen H, Stentoft J, Richter J, Koskenvesa P, Höglund M, Dreimane A, et al
Leukemia 2016 Sep;30(9):1853-60

PathologyPublication